Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1Phase 1/2 1

Status

Terminated 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3Gynecologic 1Gastrointestinal 1

Conditions

Breast Neoplasms 28Neoplasm Metastasis 9Neoplasms 8Brain Neoplasms 5Triple Negative Breast Neoplasms 3Recurrence 3Prostatic Neoplasms 3Ovarian Neoplasms 3Neoplasms by Site 3Glioma 3Endometrial Neoplasms 3Breast Diseases 3Squamous Cell Carcinoma of Head and Neck 2Meningioma 2Liposarcoma 2Head and Neck Neoplasms 2Uterine Cervical Neoplasms 1Unilateral Breast Neoplasms 1Spinal Cord Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma, Kaposi 1Sarcoma, Ewing 1Sarcoma 1Recurrent Ovarian High Grade Serous Adenocarcinoma 1Pathologic Complete Response 1Pancreatic Neoplasms 1Neurofibromatosis 1 1Neoplasms, Squamous Cell 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1

Interventions

Magnetic Resonance Spectroscopy 49enzalutamide 46apalutamide 36Specimen Handling 34Androgen Antagonists 30Abiraterone Acetate 29Radiosurgery 27Prednisone 26darolutamide 25Docetaxel 23Pluvicto 22abiraterone 20Radiotherapy 19Biopsy 17Leuprolide 15relugolix 11gallium 68 PSMA-11 11acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 11Surveys and Questionnaires 11Radiation 112-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 11Standard of Care 10Nivolumab 10cabazitaxel 9X-Rays 9Triptorelin Pamoate 9bicalutamide 8Carboplatin 8pembrolizumab 7olaparib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Prostatic Neoplasms × abemaciclib × 90 days × Clear all
NCT06630325 2026-04-28

A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer

OHSU Knight Cancer Institute

Phase 2 Terminated
6 enrolled 3 charts
GastrointestinalGenitourinaryGynecologic

Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

NCT03706365 2026-04-24

CYCLONE 2

Eli Lilly and Company

Phase 2/3 Active not recruiting
393 enrolled 23 charts
Genitourinary

Prostatic Neoplasms

NCT05113537 2026-04-13

UPLIFT

University of California, San Francisco

Phase 1/2 Recruiting
30 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡